Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus

Antiviral Research

Volumn 55, Issue 1, 2002, Pages 27-40

  Julander, Justin G ^a   Sidwell, Robert W ^a   Morrey, John D ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

3TC; Adefovir dipivoxil; Hepatitis B virus (HBV); Transgenic mouse

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BLEEDING; BLOOD LEVEL; CHROMOSOME; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEEDING; GENE LOCATION; HEPATITIS B; HEPATITIS B VIRUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA TRANSCRIPTION; TRANSGENE; TRANSGENIC MOUSE; VIRUS GENE; VIRUS INHIBITION; VIRUS LOAD; ANIMAL; BLOOD; DISEASE MODEL; DOSE RESPONSE; GENETICS; ISOLATION AND PURIFICATION; LIVER; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; TIME; VIROLOGY;

ADENINE; ADMINISTRATION, ORAL; ANIMAL; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS B; HEPATITIS B VIRUS; LAMIVUDINE; LIVER; MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; VIRAL LOAD; ANIMALS; PHOSPHONIC ACIDS;

ALEUTIAN MINK DISEASE PARVOVIRUS (STRAIN G); ANIMALIA; HEPATITIS B VIRUS; MUS MUSCULUS;

EID: 0035997922     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00223-6     Document Type: Article

References (38)

1. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study
2. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates
3. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice
4. Hepatitis B virus immunopathogenesis
5. Hepatitis B virus transgenic mice: Insights into the virus and the disease
6. Hepatitis B virus transgenic mice: Models of virus immunobiology and pathogenesis
7. Perspectives series: Host/pathogen interactions
8. Perspectives for the treatment of hepatitis B virus infections
9. Cross-resistance testing of antihepanaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
10. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man
11. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) clone in E. coli
12. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B infection
13. Preparation and analysis of RNA
14. High-level hepatitis B virus replication in transgenic mice
15. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations
16. Evaluation of anti-hepatitis B virus (HBV) drugs using the HBV transgenic mouse: Application of the semiquantitative polymerase chain reaction (PCR) for serum HBV DNA to monitor the drug efficacy
17. Profound suppression of hepatitis B virus replication with lamivudine
18. Two-cell blockage of FVB/N embryo development: An artifact of cell culture
19. Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine
20. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection
21. Animal models for HBV infections-transgenic mice
22. Adefovir dipivoxil
23. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
24. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
25. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax)
26. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
27. Treatment of hepatitis C virus with interferon and ribavirin
28. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice
29. Chemokines, inflamation and the immune system
30. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
31. 9-(2-Phosphonylmethoxyethyl) adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system
32. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo
33. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine
34. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenovir, I-FMAU, DAPD, penciclovir and lobucavir
35. Inhibition of murine macrophage nitric oxide synthase expression by a pivoxil prodrug of antiviral acyclic nucleotide analogue 9-(2-phosphonomethoxyethyl)adenine
36. Stimulation of cytokine and nitric oxide production by acyclic nucleoside phosphonates